Association of alpha-aminoadipic acid with cardiometabolic risk factors in healthy and high-risk individuals

Stacy Desine[1†], Curtis L. Gabriel[2,3†], Holly M. Smith[1],
Olivia R. Antonetti[1], Chuan Wang[1], M. Wade Calcutt[4],
Amanda C. Doran[1], Heidi J. Silver[2], Sangeeta Nair[5],
James G. Terry[5], John Jeffrey Carr[5], MacRae F. Linton[1],
Jonathan D. Brown[1], John R. Koethe[6] and Jane F. Ferguson [ID][1*]

[1]Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, United States,
[2]Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center,
Nashville, TN, United States, [3]Tennessee Center for AIDS Research, Vanderbilt University Medical
Center, Nashville, TN, United States, [4]Department of Biochemistry, Mass Spectrometry Research
Center, Vanderbilt University, Nashville, TN, United States, [5]Department of Radiology and Radiological
Sciences, Vanderbilt University Medical Center, Nashville, TN, United States, [6]Division of Infectious
Diseases, Vanderbilt University Medical Center, Nashville, TN, United States

Introduction: Plasma levels of the metabolite alpha-aminoadipic acid (2-AAA) have been associated with risk of type 2 diabetes (T2D) and atherosclerosis. However, little is known about the relationship of 2-AAA to other cardiometabolic risk markers in pre-disease states, or in the setting of comorbid disease.

Methods: We measured circulating 2-AAA using two methods in 1) a sample of 261 healthy individuals (2-AAA Study), and 2) in a sample of 134 persons comprising 110 individuals with treated HIV, with or without T2D, a population at high risk of metabolic disease and cardiovascular events despite suppression of circulating virus, and 24 individuals with T2D without HIV (HATIM Study). We examined associations between plasma 2-AAA and markers of cardiometabolic health within each cohort.

Results and discussion: We observed differences in 2-AAA by sex and race in both cohorts, with higher levels observed in men compared with women, and in Asian compared with Black or white individuals (P<0.05). There was no significant difference in 2-AAA by HIV status within individuals with T2D in the HATIM Study. We confirmed associations between 2-AAA and dyslipidemia in both cohorts, where high 2-AAA associated with low HDL cholesterol (P<0.001) and high triglycerides (P<0.05). As expected, within the cohort of people with HIV, 2-AAA was higher in the setting of T2D compared to pre-diabetes or normoglycemia (P<0.001). 2-AAA was positively associated with body mass index (BMI) in the 2-AAA Study, and with waist circumference and measures of visceral fat volume in HATIM (all P<0.05). Further, 2-AAA associated with increased liver fat in persons with HIV (P<0.001). Our study confirms 2-AAA as a marker of cardiometabolic risk in both healthy individuals and those at high cardiometabolic risk, reveals relationships with adiposity and hepatic steatosis, and highlights important differences by sex and race. Further studies are warranted to establish molecular mechanisms linking 2-AAA to disease in other high-risk populations.

KEYWORDS

2-AAA, diabetes, cardiometabolic disease, HIV, biomarker

Introduction

Cardiometabolic diseases, including diabetes and cardiovascular disease (CVD) are increasing in prevalence globally and represent a major contributor to mortality (1). Known risk factors include obesity, dyslipidemia, dysregulated glucose metabolism and inflammation (2). However, after accounting for these risk factors there remains a high degree of variability in disease susceptibility. There is a clear need for more refined biomarkers of cardiometabolic risk to improve our understanding of the underlying disease mechanisms and to improve prediction and treatment of at-risk individuals.

Cardiometabolic diseases are characterized by changes in metabolism that may contribute to disease pathophysiology, or may act as biomarkers of disease progression (3). Circulating metabolites that associate with disease states can shed light on underlying disease etiology, biological mechanisms, and may have clinical utility for prediction (4). Strategies to identify individuals at high cardiometabolic risk and to modulate disease processes in these individuals before onset of overt disease, would have significant impact in reducing mortality, morbidity, and healthcare costs. For this approach to be successful, early biomarkers of disease that predict at-risk individuals are required, as well as discovering novel pathways for therapeutic targeting. To this end, studying both healthy individuals, as well as individuals with conditions that place them at higher risk of cardiometabolic diseases, may provide an important model to identify novel physiologic relationships.

The metabolite alpha-aminoadipic acid (2-AAA) is associated with the development of type 2 diabetes (T2D) (5) and atherosclerosis (6), potentially identifying at-risk individuals before development of other known risk markers (7). Relatively little is known about the function of 2-AAA, or potential mechanisms linking 2-AAA to disease. 2-AAA is derived from the breakdown of the essential amino acid lysine, and is primarily metabolized within mitochondria, with potential involvement in oxidative stress (8, 9). Elevated 2-AAA is associated with increased insulin secretion, obesity, and dysregulated mitochondrial metabolism (5, 7, 10–13). This makes 2-AAA an interesting novel candidate in cardiometabolic disease biology. However, the relationships between 2-AAA and other cardiometabolic risk markers have not been well-described.

The purpose of this study was to characterize the association between 2-AAA and other demographic and circulating markers in a sample of healthy individuals, as well individuals at high risk of metabolic and cardiovascular disease. As chronic viral infections, including treated human immunodeficiency virus (HIV), predispose individuals to a higher incidence of cardiometabolic disease and earlier onset, these conditions can serve as an models of exaggerated or accelerated risk to further identify important physiologic relationships (14–17). Here, we assess the relationship of 2-AAA with range of cardiometabolic disease conditions and risk factors among healthy individuals and those with treated HIV infection.

Materials and methods

Study populations

Samples and data from two independent studies are included here. Participants of both studies were recruited from the same geographic area (Nashville, TN, and surrounding areas), and study procedures completed at Vanderbilt University Medical Center.

Determinants of 2-AAA: screening study

Healthy adults (non-pregnant and non-lactating women and men, age 18-45 years) were recruited to complete a single study visit as part of a cross-sectional study at Vanderbilt University Medical Center between November 2018 and June 2021. Exclusion criteria included body mass index (BMI) >30 kg/m^2, active use of tobacco products, active use of prescription medications (apart from hormonal birth control), and diagnosis of diabetes mellitus, cardiovascular disease, renal disease, liver disease, or bleeding disorders. Data for 261 individuals who completed study procedures (vital signs, anthropometric measurements), provided a fasting blood sample, and had sufficient plasma available for 2-AAA measurement are included in the current analysis. All participants provided written, informed consent, and the study was approved by the Vanderbilt University Institutional Review Board.

The HIV, adipose tissue immunology, and metabolism study

Adults with human immunodeficiency virus (HIV, N=112) were recruited from the Vanderbilt Comprehensive Care Clinic between August 2017 and November 2019. Participants were on combination antiretroviral therapy (ART) for ≥18 months, with a minimum of 12 months of sustained suppression of plasma viremia at enrollment and had no known inflammatory or rheumatologic conditions. Exclusion criteria were self-reported heavy alcohol use (>11 drinks/week), known cirrhosis, active hepatitis B or C, cocaine or amphetamine use, and use of corticosteroids or growth hormones. By design and to enrich for the presence of cardiometabolic disease, the cohort enrolled approximately equal numbers of individuals who were normoglycemic (HbA1c < 5.7 or fasting blood glucose (FBG) < 100 mg/dL); pre-diabetes (HbA1c 5.7%-6.4% and/or FBG 100-126 mg/dL); and diabetes (HbA1c ≥ 6.4%, and/or FBG ≥ 126 mg/dL or on diabetes medication). To allow for direct comparison of 2-AAA levels with HIV-negative individuals, the study also recruited individuals with diabetes but without HIV (N=24). Participants provided written, informed consent, and the study was approved by the Vanderbilt University Institutional Review Board (ClinicalTrials.gov Identifier: NCT04451980).

Measurement of 2-AAA

In the *2-AAA Study*, plasma levels of 2-AAA were quantified by liquid chromatography mass spectrometry (LCMS) at the Vanderbilt Mass Spectrometry Core. Samples were spiked with internal standard (Arginine-15N4, Sigma Aldrich), extracted with methanol, and derivatized with dansyl chloride (Sigma Aldrich) prior to analysis. The dansyl derivative of 2-AAA ([M+H]+ 395.1271) was measured by targeted selected ion monitoring (SIM) using a Vanquish ultrahigh performance liquid chromatography (UHPLC) system interfaced to a QExactive HF quadrupole/orbitrap mass spectrometer (Thermo Fisher Scientific). Data acquisition and quantitative spectral analysis were conducted using Thermo-Finnigan Xcaliber version 4.1 and Thermo-Finnigan LCQuan version 2.7, respectively. Calibration curves were constructed by plotting peak area ratios (2-AAA/Arg-15N4) against analyte concentrations for a series of 2-AAA standards. Electrospray ionization source parameters were tuned and optimized using an authentic 2-AAA reference standard (Sigma Aldrich) derivatized with dansyl chloride and desalted by solid phase extraction prior to direct liquid infusion.

In the *HATIM Study*, plasma 2-AAA was measured as part of a metabolomics panel, at the Southeast Center for Integrated Metabolomics (SECIM) at the University of Florida, using previously described methods [18, 19]. Briefly, plasma samples were spiked with internal standards solution. Proteins were precipitated using 8:1:1 Acetonitrile: Methanol: Acetone (Fisher Scientific, San Jose, CA), and the supernatant dried under a gentle stream of nitrogen at 30°C (Organomation Associates, Inc., Berlin, MA). Samples were reconstituted with injection standards solution. LC-MS untargeted metabolomics was performed on a Thermo Q-Exactive Orbitrap mass spectrometer equipped with a Dionex UPLC system (Thermo, San Jose, CA). Percent relative standard deviation of internal standard peak areas were calculated to evaluate extraction and injection reproducibility. Mzmine 2 was used to identify features, deisotope, align features and perform gap filling. The data was searched against SECIM internal retention time metabolite library. All adducts and complexes were identified and removed from the data set. Ion counts from features mapping to alpha-aminoadipic acid in positive ion mode were summed for analysis. Because measurement of 2-AAA was conducted at different sites, studies were analyzed separately.

Lipid and biomarker measurement

In the *2-AAA Study*, serum lipids were profiled at the Vanderbilt Lipid Laboratory. Briefly, total cholesterol and triglycerides (TG) were measured by standard enzymatic assays. High-density lipoprotein (HDL) was measured with the enzymatic method after precipitation of VLDL and LDL using polyethylene glycol reagent (PEG). LDL cholesterol was calculated using the Friedewald equation [20]. In the *HATIM Study*, fasting plasma HDL, LDL, and TG were measured using the selective enzyme hydrolysis method (Abbott, Chicago, IL). In the 2-AAA Study, fasting glucose was measured at the study visit by finger prick

(AimStrip Plus Blood Glucose Meter, Germaine Laboratories Inc., San Antonio TX). In the HATIM Study, insulin was measured by radioimmunoassay (Millipore Cat. # PI-13K). The assay utilizes ^{125}I-labeled insulin and a double antibody/PEG technique to determine serum insulin levels. The assay was modified by the Vanderbilt Hormone and Analytical Services Core to improve the sensitivity to 1uU/ml(0.04ng/ml). Glucose and hemoglobin A1c (HbA1c) were measured in fasting blood samples at the Vanderbilt Clinical Chemistry Laboratory.

Body composition analysis

In the *HATIM Study*, individuals underwent computed tomography (CT) imaging using a Siemens Somatom Force multidetector scanner (Erlangen, Germany) to acquire chest, abdominal and liver images, as described [21, 22]. Briefly, separate non-contrast electrocardiogram-gated thorax (top of the aortic arch through the lung base) and abdominal (diaphragm to lumbosacral junction) scans were performed using a scanning protocol and image interpretation approach previously described [23–25]. Abdominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) volumes were measured within a 10-mm block of images consisting of eight images, 1.25-mm thick, at the L4-5 vertebrae using Osirix software. Pericardial adipose tissue (PAT) volume was measured within a 45-mm block of images spanning 15 mm above and 30 mm below the superior extent of the left main coronary artery, which includes the adipose tissue located around the epicardial coronary arteries (left main coronary, left anterior descending, right coronary, and circumflex arteries) as well as the epicardial and PAT around the coronary arteries [26, 27]. Images at T12-L1 were used to identify the liver below the right diaphragm corresponding to superior aspects of the right and medial lobes or hepatic segments 4a, 7, and 8 using the Couinaud classification system. Three regions of interest within homogenous portions of the liver at three levels were identified and liver density was averaged from the nine total regions. Tissue radiodensity was quantified using the Hounsfield Units scale where water has a value of 0 HU and air has a value of -1000 HU.

Statistical analysis

Plasma 2-AAA was assessed for normality of distribution through visualization, and testing for skewness and kurtosis, and was found to follow a normal distribution in both the 2-AAA and HATIM studies. Two individuals were considered outliers for 2-AAA in HATIM (>3 SD from the mean) and were removed prior to analysis. Associations between 2-AAA and continuous variables were analyzed using linear regression models and correlation analysis. Analyses between 2-AAA and discrete variables were analyzed by T-test or ANOVA. Models were adjusted for sex and race in both studies and for additional covariates in HATIM (smoking, diabetes group). Inclusion of age in the model did not alter the results, and was not included in the base models. Models were further adjusted for other risk factors as indicated in the

corresponding results sections, including BMI, cholesterol, HDL, LDL, TG, fasting glucose. P<0.05 was considered statistically significant, and Bonferroni P<0.05 considered statistically significant for *post hoc* multiple testing correction. Analyses were completed and results visualized using IBM SPSS Statistics version 28 (IBM, Armonk NY) and GraphPad Prism version 9.4.1 (GraphPad Software, San Diego, CA).

Results

The characteristics of the participants of the 2-AAA Study are shown in Table 1. Characteristics of the participants of the HATIM Study are shown in Table 2. Participants of the 2-AAA study were 72% female, and 74% white, with an average age of 28 years. Participants of the HATIM study were 67% male, and 54% white, with an average age of 48 years. Plasma 2-AAA in persons with HIV (PWH) with diabetes (ion count $312 \times 10^4 \pm 75 \times 10^4$) was slightly higher than that in HIV-negative with diabetes (ion count $271 \times 10^4 \pm 74 \times 10^4$), but the difference was not statistically significant (P=0.08).

Plasma 2-AAA levels are higher in men than in women, and higher in Asian individuals

There was a significant difference in plasma 2-AAA by sex in the 2-AAA Study, with higher levels in men than in women (plasma 2-AAA 95.99 ± 33.7 vs. 68.43 ± 27.7 ng/ml, P<0.0001; Figure 1A). A similar difference by sex was observed in the HATIM Study samples, with higher levels in men than women (plasma 2-AAA ion count $281 \times 10^4 \pm 73 \times 10^4$ vs. $242 \times 10^4 \pm 65 \times 10^4$ ion count, P=0.004; Figure 1C). Because other risk factors also differ by sex, we

performed stepwise linear regression models including risk factors (age, BMI, fasting glucose, cholesterol, HDL, LDL, TG), and found that the associations with sex remained significant (P<0.001 *2-AAA Study*, P<0.02 *HATIM Study*). We observed a significant difference by self-reported race in the 2-AAA Study (Overall P=0.002; Figure 1B), with individuals self-identifying as Asian having borderline significantly higher plasma 2-AAA (95.68 ± 35.5 ng/ml) compared with individuals self-identifying as Black or African American (72.26 ± 30.0 ng/ml, P=0.05), or white (72.73 ± 30.7 ng/ml, P=0.007). This was not attributable to differences in sex distribution, age, or risk factors between groups. In fact, Asian individuals in the 2-AAA Study had significantly lower BMI (P=0.018) and systolic blood pressure (P=0.005) than other individuals. Interestingly, there was also an overall difference by self-reported race in the HATIM sample (P=0.014; Figure 1D), with a trend towards higher levels of 2-AAA in Asian (2-AAA ion count $359 \times 10^4 \pm 45 \times 10^4$) compared to Black (2-AAA ion count $249 \times 10^4 \pm 65 \times 10^4$) and white (2-AAA ion count $279 \times 10^4 \pm 75 \times 10^4$) individuals, although there were only three individuals self-identifying as Asian in this sample, so the differences did not reach statistical significance in *post hoc* tests. There was no association between 2-AAA and age in either dataset (2-AAA Study $r^2 = 0.028$, P=0.65; HATIM $r^2 = 0.092$, P=0.26).

Plasma 2-AAA levels associate with dyslipidemia in healthy individuals and PWH

Higher plasma 2-AAA was associated with lower HDL cholesterol (2-AAA Study $r^2 = -0.267$, P<0.001; HATIM $r^2 = -0.579$, P<0.001; Figures 2A, B), and higher triglycerides (2-AAA Study $r^2 = 0.246$, P=0.027; HATIM $r^2 = 0.526$, P=0.007; Figures 2C, D). There was no significant association with LDL cholesterol.

TABLE 1   Characteristics of the participants of the 2-AAA Screening Study.

	Male (N=72)	Female (N=189)
	Mean (SD)	Mean (SD)
Age (years)	28.96 (6.92)	27.76 (7.2)
Race (N [%] Black, white, Asian, other)	3, 55, 8, 6 [4, 77, 11, 8%]	14, 139, 25, 11 [7, 74, 13, 6%]
BMI (kg/m²)	24.77 (2.9)	22.94 (2.9)
Systolic Blood Pressure (mmHg)	120.57 (13.5)	111.26 (10.7)
Diastolic Blood Pressure (mmHg)	73.80 (9.5)	69.67 (8.1)
Glucose (mg/dL)	90.0 (7.6)	91.18 (8.2)
Total cholesterol (mg/dL)	166.56 (30.7)	167.94 (32.4)
HDL (mg/dL)	53.47 (10.7)	64.67 (13.1)
LDL (mg/dL)	95.56 (24.9)	87.41 (24.5)
TG (mg/dL)	87.44 (37.5)	79.29 (37.1)
2-AAA (ng/ml)	95.99 (33.8)	68.44 (27.7)

TABLE 2 Characteristics of participants of the HATIM Study.

	PWH						HIV-negative	
	Insulin sensitive		Pre-Diabetes		Diabetes		Diabetes	
	Male (N=33)	Female (N=8)	Male (N=27)	Female (N=7)	Male (N=24)	Female (N=11)	Male (N=6)	Female (N=18)
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
Age (years)	42.15 (11.7)	46.37 (7.7)	44.40 (12.2)	49.14 (10.2)	52.62 (9.4)	48 (12.0)	51.33 (12.1)	57.61 (9.6)
Race (N [%] Black, white, Asian, other)	10, 22, 1, 0 [30, 67, 3, 0%]	5, 2, 0, 1 [63, 25, 0, 12%]	11, 14, 1, 1 [40, 52, 4, 4%]	4, 3, 0, 0 [57, 43, 0, 0%]	10, 14, 0, 0 [42, 58, 0, 0%]	7, 1, 0, 3 [64, 9, 0, 27%]	1, 5, 0, 0 [17, 83, 0, 0%]	6, 11, 1, 0 [33, 61, 6, 0%]
BMI (kg/m^2)	30.78 (3.8)	34.21 (5.8)	33.28 (6.3)	34.03 (6.1)	34.76 (7.25)	40.01 (9.8)	38.16 (8.8)	37.31 (5.1)
Waist circumference (cm)	100.39 (12.6)	104 (12.5)	105.40 (13.9)	102.86 (14.8)	115.21 (12.6)	114.7 (17.5)	126.31 (20.4)	114.7 (13.85)
Total cholesterol (mg/dL)	174.63 (38.3)	186.6 (23.0)	175.7 (35.1)	223.71 (38.5)	173.75 (33.1)	179.45 (41.3)	183.66 (85.8)	171.44 (27.9)
LDL (mg/dL)	102.12 (34.1)	110.3 (18.8)	110.77 (44.9)	129 (35)	91.39 (28.9)	95.2 (33.9)	86.83 (27.0)	102.0 (27.1)
HDL (mg/dL)	47.06 (18.2)	54.1 (15.9)	41.22 (13.3)	65.43 (23.6)	37.96 (10.5)	49.72 (12.9)	36.33 (10.1)	47.55 (8.8)
TG	127.27 (82.9)	111.8 (64.2)	154.89 (83.4)	146.86 (56.8)	250.29 (224.9)	189.27 (145.4)	327.16 (470.9)	109.33 (45.4)
Glucose (mg/dL)	87.0 (9.5)	89.38 (6.0)	111.55 (14.0)	112.42 (8.1)	203.6 (88.4)	156 (59.7)	164.33 (78.5)	128.61 (34.9)
Insulin (uU/mL)	19.19 (23.0)	18.39 (19.4)	55.06 (59.2)	30.9 (24.9)	38.58 (21.2)	36.62 (19.3)	46.99 (29.4)	28.92 (16.3)
HOMA-IR	4.23 (4.9)	4.24 (4.8)	14.91 (15.6)	9.10 (7.7)	22.63 (19.1)	16.49 (14.8)	17.78 (13.0)	8.73 (6.5)
Hemoglobin A1c (%)	5.1 (0.46)	5.16 (0.23)	5.52 (0.5)	5.52 (0.3)	8.18 (2.3)	7.10 (1.8)	7.81 (2.0)	6.85 (0.93)
Liver attenuation (HU)	61.44 (7.5)	63.87 (3.4)	62.17 (9.1)	61.3 (12.9)	53.03 (14.6)	57.54 (11.5)	48.25 (11.6)	45.62 (19.0)
Plasma 2-AAA (ion count)	2441358 (623282)	1898487 (225878)	2769029 (548804)	2059280 (355932)	3270163 (715556)	2794366 (739755)	3141535 (969840)	2576285 (622577)

Higher plasma 2-AAA levels associate with diabetes status in PWH

There were significant differences in plasma 2-AAA by diabetes status within PWH in the HATIM sample (P<0.001, Figure 3). Individuals with diabetes had significantly higher levels of 2-AAA (ion count $312x10^4 \pm 75x10^4$) than both the insulin sensitive (ion count $233x10^4 \pm 60x10^4$, P<0.001) and the pre-diabetic (ion count $262x10^4 \pm 58x10^4$, P=0.005) groups in models adjusted for sex, race, BMI and smoking status.

Plasma 2-AAA associates with elevated fasting glucose, insulin, and HbA1c in PWH

Across all PWH individuals in HATIM, plasma 2-AAA was associated with increased fasting glucose (r^2 = 0.576, P<0.001), fasting insulin (r^2 = 0.623, P<0.001), HOMA-IR (r^2 = 0.538, P<0.001) and hemoglobin A1c (r^2 = 0.580, P<0.001). In secondary analyses split by diabetes status, 2-AAA associated with glucose and HbA1c only in the individuals with diabetes (glucose r^2 = 0.52, HbA1c r^2 = 0.58; both P<0.0001 for diabetes, vs P>0.5 for insulin sensitive and pre-diabetes), but 2-AAA was associated with

insulin in both people with and without diabetes (r^2 = 0.27, P<0.02 insulin sensitive, r^2 = 0.5, p<0.001 pre-diabetes, r^2 = 0.26, P<0.002 diabetes). In the 2-AAA Study, a small number of people (n=25) had evidence of potential impaired fasting glucose (IFG, defined as glucose >100mg/dL but <125 mg/dL). While plasma 2-AAA levels were slightly higher within the individuals with IFG (82.5 vs. 75.4 ng/ml), this difference did not reach statistical significance.

Elevated plasma 2-AAA levels associate with differences in anthropometrics, adipose tissue, and liver density

We found a significant association between plasma 2-AAA and higher BMI in the 2-AAA Study (r^2 = 0.275, P<0.001, model adjusted for sex and race), but this was not significant in HATIM. However, in HATIM, higher plasma 2-AAA was significantly associated with increased waist circumference (r^2 = 0.219, P<0.001), as well as greater visceral adipose tissue volume (r^2 = 0.225, P<0.001), but not with measures of subcutaneous or pericardial adipose tissue. In HATIM, 2-AAA was negatively associated with liver density (r^2 = 0.192, P=0.003; Figure 4). Lower liver density is a marker of higher proportion of ectopic fat in the liver.

FIGURE 1
Plasma 2-AAA is significantly higher in men than women in the 2-AAA **(A)** and HATIM Study **(C)**. 2-AAA is higher in Asian compared to Black or white individuals in the 2-AAA Study **(B)** with a similar trend in the HATIM Study **(D)**. Data are expressed as ng/ml for data from the 2-AAA Study and ion counts for the HATIM study.

FIGURE 2
Plasma 2-AAA associates with lower HDL cholesterol and higher Triglycerides in the 2-AAA **(A, C)** and HATIM **(B, D)** studies. Data are expressed as ng/ml for data from the 2-AAA Study and ion counts for the HATIM study.

FIGURE 3
Plasma 2-AAA was significantly higher in PWH and diabetes, compared with PWH who were insulin sensitive or with pre-diabetes.

Discussion

We measured plasma 2-AAA in two independent samples of individuals across the spectrum of healthy (no diagnosed diseases) to high cardiometabolic risk (diabetes and treated HIV infection). 2-AAA was elevated in diabetes but did not appear to be significantly elevated based on HIV status. We found that plasma 2-AAA is elevated in men compared with women, and in Asian compared with other self-identified ancestries. These associations are consistent in both healthy individuals and PWH. We confirmed associations between 2-AAA and both low HDL and high TG, and between 2-AAA and diabetes. We report novel relationships between 2-AAA and visceral adipose tissue measured by CT, and between 2-AAA and higher liver fat. Our data highlight consistent relationships between 2-AAA and cardiometabolic risk markers across two different sample groups, and further confirm 2-AAA as an important candidate biomarker with broad relevance for additional prognostic and therapeutic consideration.

Plasma 2-AAA levels differed by sex, an association that has been reported previously in Mexican young adults (28). Men have relatively higher risk of CVD than pre-menopausal women, yet the mechanisms underlying this difference are not fully understood (1). We further report differences by self-reported race, with Asian individuals having higher 2-AAA than other groups. Individuals of Asian ancestry have relatively higher risk of T2D and some CVD compared with individuals of European ancestry with the same risk factor profile (29, 30). The mechanisms underlying this are incompletely understood, and the risk factors for CVD in Asians may differ when compared with European ancestry (31). While the original discovery of 2-AAA as a diabetes metabolite was in

FIGURE 4
Plasma 2-AAA was negatively associated with liver attenuation in the HATIM Study of PWH.

European ancestry (5), 2-AAA has also been reported to associate with T2D in Chinese individuals (32). Whether differences in 2-AAA may play a role in mediating the relative increased risk in men compared with women, and Asian compared with other ancestries, remains to be determined.

We previously reported that plasma 2-AAA associates with both lower HDL cholesterol and higher triglycerides (33). We replicated those associations in the current study, establishing that this relationship is consistent across multiple different samples, including in a cohort of persons with HIV. Based on genetic evidence, 2-AAA drives the decrease in HDL (33). While low HDL cholesterol is consistently associated with increased cardiometabolic risk (34, 35), interventions to alter HDL have shown no benefit (36). This could be due to differences in HDL composition or function, or due to a causal biomarker that is upstream of HDL. This raises the intriguing hypothesis that elevated 2-AAA, rather than low HDL per se, may be driving increased cardiometabolic risk. However, careful mechanistic studies are required to interrogate this further.

2-AAA was originally discovered as a predictor of diabetes, and is associated with increased insulin secretion in animal models and cells (5). In the setting of experimental hyperglycemia in overweight and obese, but otherwise healthy individuals, 2-AAA was significantly decreased following 24 hours of hyperglycemia (37). 2-AAA has been shown to be reduced in the acute setting in response to insulin infusion (38). We found that 2-AAA was significantly higher in PWH who have diabetes, than in PWH who were insulin sensitive or pre-diabetic. This is similar to what has been reported in HIV-negative individuals (5, 39), and suggests that the relationship between 2-AAA and diabetes is consistent across different settings, including against the background of well-controlled HIV infection, a population at increased risk of cardiometabolic disease (17). We found no significant difference in plasma 2-AAA levels based on HIV status in the HATIM cohort within the subset of individuals with diabetes, further suggesting that 2-AAA is a useful biomarker of cardiometabolic risk in multiple at-risk populations. 2-AAA was associated with increased fasting glucose, fasting insulin, and hemoglobin A1c in the HATIM study. However, the association between 2-AAA and glucose was only significant in individuals with diabetes; 2-AAA was not associated with fasting glucose in insulin sensitive individuals in the 2-AAA Study or HATIM, or in individuals with pre-diabetes in HATIM. In contrast, 2-AAA was associated with higher insulin in individuals with and without diabetes. This distinction between the glycemic and insulin axis is consistent with the hypothesis that 2-AAA is an early marker or driver of hyperinsulinemia and is associated with elevated insulin before the development of overt hyperglycemia or diabetes. These data further support a mechanism where elevated 2-AAA precedes the onset of hyperglycemia, and associates with hyperinsulinemia even in individuals who appear insulin sensitive. Associations between 2-AAA and hyperglycemia are likely secondary to insulin resistance. However, further in-depth studies are required to assess potential reciprocal regulation of 2-AAA and insulin.

2-AAA was positively associated with BMI in the 2-AAA study, but not in the HATIM study. However, there was a significant association between 2-AAA and waist circumference in HATIM. This may suggest that the relationship between 2-AAA and adiposity is modulated by HIV-associated effects on adipose distribution (40). Previous studies have also highlighted an association between 2-AAA and obesity, including both BMI and waist circumference (7, 11, 41, 42). While one study has found that 2-AAA is protective against obesity and diabetes in mice (43), these findings are in contrast to all other studies, and may be related to specific metabolic anomalies in the mouse model used (13, 44, 1). In our study, 2-AAA associated with increased visceral fat in HATIM, but not subcutaneous or pericardial fat. These data are consistent with a previous study, where 2-AAA was associated with metabolically unhealthy central obesity, compared with metabolically healthy peripheral obesity (45). Thus, 2-AAA may relate specifically to pathogenic adipose tissue dysfunction, rather than to obesity itself.

Plasma 2-AAA associated with lower liver density, which corresponds to higher liver fat, and is considered a measure of hepatic steatosis. Previous data in mice found an association between 2-AAA and liver mass (10), however, to our knowledge our study describes this for the first time in humans. Elevated 2-AAA may thus be a risk factor for hepatic steatosis and development of fatty liver disease, however, whether this is independent of associations with BMI, visceral fat and circulating lipids remains to be determined.

Our study had several strengths. We analyzed plasma 2-AAA in two separate samples of well-phenotyped individuals, recruited from the same geographic area, to the same academic medical center. Our studies included both healthy individuals, and PWH across the diabetes spectrum, allowing us to assess whether the relationship between 2-AAA and cardiometabolic risk markers is consistent in the settings of chronic viral-induced inflammation as well as in individuals without diagnosed disease. 2-AAA was not measured in many previous metabolomic studies, and is not consistently detected or reported on popular metabolomics panels (e.g. Metabolon). Thus, the importance of this metabolite in cardiometabolic health may be under-appreciated. We used a targeted assay in the 2-AAA study to quantify 2-AAA, providing important data on circulating levels in healthy individuals. To our knowledge, this is the first study to measure associations between 2-AAA and metabolic disease in PWH. PWH suffer a disproportionate burden of diabetes, hypertension, fatty liver, and dyslipidemia compared to HIV negative persons (46–49), and allows for validation of the relevance of 2-AAA to disease within the setting of a highly-inflammatory exaggerated phenotype. Our study also had some limitations. Plasma 2-AAA was measured using a different method in HATIM compared with the 2-AAA study, limiting our ability to directly compare levels of 2-AAA in PWH compared with healthy individuals. However, we were able to compare levels between PWH and HIV-negative within a subset of individuals with diabetes. We also had limited sample size to fully characterize the differences by race across both samples, with small

numbers of Black individuals in the 2-AAA study and small numbers of Asian individuals in the HATIM study.

In conclusion, our study establishes differences in plasma 2-AAA by sex and race, confirms associations between 2-AAA and dyslipidemia in both healthy individuals and PWH with or without diabetes, and highlights novel relationships between 2-AAA and liver fat and visceral adipose tissue. Further mechanistic and longitudinal studies are required to establish whether 2-AAA is causally linked to cardiometabolic disease.

Data availability statement

The data presented in the study are deposited in the Figshare repository, accession number 10.6084/m9.figshare.24074379.

Ethics statement

The studies involving human participants were reviewed and approved by Vanderbilt University Institutional Review Board (IRB). The patients/participants provided their written informed consent to participate in this study.

Author contributions

Study design: SD, CG, JK, JF. Acquisition, analysis and interpretation of data: SD, CG, HS, OA, CW, MC, AD, HS, SN, JT, JC, ML, JB, JK, JF. Drafted the manuscript: SD, CG, JF. Revised the manuscript and approved publication: SD, CG, HS, OA, CW, MC, AD, HS, SN, JT, JC, ML, JB, JK, JF. All authors contributed to the article and approved the submitted version.

Funding

Acknowledgments

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: A report from the American Heart Association. *Circulation* (2022) 145:e153–639. doi: 10.1161/CIR.0000000000001052

2. Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. *Circulation* (2018) 138:1100–12. doi: 10.1161/CIRCULATIONAHA.117.033369

3. Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. *J Lipids* (2015) 2015:1–50. doi: 10.1155/2015/971453

4. Chu X, Jaeger M, Beumer J, Bakker OB, Aguirre-Gamboa R, Oosting M, et al. Integration of metabolomics, genomics, and immune phenotypes reveals the causal roles of metabolites in disease. *Genome Biol* (2021) 22:198. doi: 10.1186/s13059-021-02413-z

5. Wang TJ, Ngo D, Psychogios N, Dejam A, Larson MG, Vasan RS, et al. 2-Aminoadipic acid is a biomarker for diabetes risk. *J Clin Invest* (2013) 123:4309–17. doi: 10.1172/JCI64801

6. Saremi A, Howell S, Schwenke DC, Bahn G, Beisswenger PJ, Reaven PD, et al. Advanced glycation end products, oxidation products, and the extent of atherosclerosis during the VA diabetes trial and follow-up study. *Diabetes Care* (2017) 40:591–8. doi: 10.2337/dc16-1875

7. Lee HJ, Jang HB, Kim W-H, Park KJ, Kim KY, Park SI, et al. 2-Aminoadipic acid (2-AAA) as a potential biomarker for insulin resistance in childhood obesity. *Sci Rep* (2019) 9:13610. doi: 10.1038/s41598-019-49578-z

8. Estaras M, Ameur FZ, Estévez M, Díaz-Velasco S, Gonzalez A. The lysine derivative aminoadipic acid, a biomarker of protein oxidation and diabetes-risk, induces production of reactive oxygen species and impairs trypsin secretion in mouse pancreatic acinar cells. *Food Chem Toxicol* (2020) 145:111594. doi: 10.1016/j.fct.2020.111594

9. Luna C, Arjona A, Dueñas C, Estevez M. Allysine and α-aminoadipic acid as markers of the glyco-oxidative damage to human serum albumin under pathological glucose concentrations. *Antioxidants (Basel)* (2021) 10:474. doi: 10.3390/antiox10030474

10. Wu Y, Williams EG, Dubuis S, Mottis A, Jovaisaite V, Houten SM, et al. Multilayered genetic and omics dissection of mitochondrial activity in a mouse reference population. *Cell* (2014) 158:1415–30. doi: 10.1016/j.cell.2014.07.039

11. Ho JE, Larson MG, Ghorbani A, Cheng S, Chen M-H, Keyes M, et al. Metabolomic profiles of body mass index in the Framingham heart study reveal distinct cardiometabolic phenotypes. *PloS One* (2016) 11:e0148361. doi: 10.1371/journal.pone.0148361

12. Plubell DL, Fenton AM, Wilmarth PA, Bergstrom P, Zhao Y, Minnier J, et al. GM-CSF driven myeloid cells in adipose tissue link weight gain and insulin resistance *via* formation of 2-aminoadipate. *Sci Rep* (2018) 8:11485. doi: 10.1038/s41598-018-29250-8

13. Wang C, Calcutt MW, Ferguson JF. Knock-out of DHTKD1 alters mitochondrial respiration and function, and may represent a novel pathway in cardiometabolic disease risk. *Front Endocrinol (Lausanne)* (2021) 12:710698. doi: 10.3389/fendo.2021.710698

14. Barale M, Massano M, Bioletto F, Maiorino F, Pusterla A, Mazzetti R, et al. Sex-specific fat mass ratio cutoff value identifies a high prevalence of cardio-metabolic

disorders in people living with HIV. *Nutr Metab Cardiovasc Dis* (2022) 32:1936–43. doi: 10.1016/j.numecd.2022.05.004

15. Gooden TE, Gardner M, Wang J, Jolly K, Lane DA, Benjamin LA, et al. Incidence of cardiometabolic diseases in people with and without human immunodeficiency virus in the United Kingdom: A population-based matched cohort study. *J Infect Dis* (2022) 225:1348–56. doi: 10.1093/infdis/jiab420

16. Rivera AS, Rusie L, Plank M, Siddique J, Beach LB, Lloyd-Jones DM, et al. Association of cumulative viral load with the incidence of hypertension and diabetes in people with HIV. *Hypertension* (2022) 79:e135–42. doi: 10.1161/HYPERTENSIONAHA.122.19302

17. Spieler G, Westfall AO, Long DM, Cherrington A, Burkholder GA, Funderburg N, et al. Trends in diabetes incidence and associated risk factors among people living with HIV in the current treatment era 2008-2018. *AIDS* (2022) 36(13):1811–1818. doi: 10.1097/QAD.0000000000003348

18. O'Kell AL, Garrett TJ, Wasserfall C, Atkinson MA. Untargeted metabolomic analysis in naturally occurring canine diabetes mellitus identifies similarities to human Type 1 Diabetes. *Sci Rep* (2017) 7:9467. doi: 10.1038/s41598-017-09908-5

19. O'Kell AL, Garrett TJ, Wasserfall C, Atkinson MA. Untargeted metabolomic analysis in non-fasted diabetic dogs by UHPLC-HRMS. *Metabolomics* (2019) 15:15. doi: 10.1007/s11306-019-1477-6

20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* (1972) 18:499–502. doi: 10.1093/clinchem/18.6.499

21. Gabriel CL, Ye F, Fan R, Nair S, Terry JG, Carr JJ, et al. Hepatic steatosis and ectopic fat are associated with differences in subcutaneous adipose tissue gene expression in people with HIV. *Hepatol Commun* (2021) 5:1224–37. doi: 10.1002/hep4.1695

22. Bailin SS, Gabriel CL, Fan R, Ye F, Nair S, Terry JG, et al. Relationship of subcutaneous adipose tissue inflammation-related gene expression with ectopic lipid deposition in persons with HIV. *J Acquir Immune Defic Syndr* (2022) 90(2):175–183. doi: 10.1097/QAI.0000000000002926

23. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR, et al. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. *Radiology* (2005) 234:35–43. doi: 10.1148/radiol.2341040439

24. VanWagner LB, Ning H, Lewis CE, Shay CM, Wilkins J, Carr JJ, et al. Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study. *Atherosclerosis* (2014) 235:599–605. doi: 10.1016/j.atherosclerosis.2014.05.962

25. Terry JG, Shay CM, Schreiner PJ, Jacobs DR, Sanchez OA, Reis JP, et al. Intermuscular adipose tissue and subclinical coronary artery calcification in midlife: the CARDIA study (Coronary artery risk development in young adults). *Arterioscler Thromb Vasc Biol* (2017) 37:2370–8. doi: 10.1161/ATVBAHA.117.309633

26. Alman AC, Jacobs DR, Lewis CE, Snell-Bergeon JK, Carnethon MR, Terry JG, et al. Higher pericardial adiposity is associated with prevalent diabetes: The Coronary Artery Risk Development in Young Adults study. *Nutr Metab Cardiovasc Dis* (2016) 26:326–32. doi: 10.1016/j.numecd.2015.12.011

27. Miljkovic I, Kuipers AL, Cvejkus RK, Carr JJ, Terry JG, Thyagarajan B, et al. Hepatic and skeletal muscle adiposity are associated with diabetes independent of visceral adiposity in nonobese African-Caribbean men. *Metab Syndr Relat Disord* (2020) 18:275–83. doi: 10.1089/met.2019.0097

28. Guevara-Cruz M, Vargas-Morales JM, Méndez-García AL, López-Barradas AM, Granados-Portillo O, Ordaz-Nava G, et al. Amino acid profiles of young adults differ by sex, body mass index and insulin resistance. *Nutr Metab Cardiovasc Dis* (2018) 28:393–401. doi: 10.1016/j.numecd.2018.01.001

29. Ma RCW, Chan JCN. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. *Ann N Y Acad Sci* (2013) 1281:64–91. doi: 10.1111/nyas.12098

30. Buljubasic N, Zhao W, Cheng J, Li H, Oemrawsingh R, Akkerhuis M, et al. Comparison of temporal changes in established cardiovascular biomarkers after acute coronary syndrome between Caucasian and Chinese patients with diabetes mellitus. *Biomarkers* (2020) 25:341–8. doi: 10.1080/1354750X.2020.1759692

31. Paul SK, Owusu Adjah ES, Samanta M, Patel K, Bellary S, Hanif W, et al. Comparison of body mass index at diagnosis of diabetes in a multi-ethnic population:

A case-control study with matched non-diabetic controls. *Diabetes Obes Metab* (2017) 19:1014–23. doi: 10.1111/dom.12915

32. Wang S, Li M, Lin H, Wang G, Xu Y, Zhao X, et al. Amino acids, microbiota-related metabolites, and the risk of incident diabetes among normoglycemic Chinese adults: Findings from the 4C study. *Cell Rep Med* (2022) 3(9):100727. doi: 10.1016/j.xcrm.2022.100727

33. Shi M, Wang C, Mei H, Temprosa M, Florez JC, Tripputi M, et al. Genetic architecture of plasma alpha-aminoadipic acid reveals a relationship with high-density lipoprotein cholesterol. *J Am Heart Assoc* (2022) 11:e024388. doi: 10.1161/JAHA.121.024388

34. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. *JAMA* (1986) 256:2835–8. doi: 10.1001/jama.1986.03380200073024

35. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. *JAMA* (2009) 302:1993–2000. doi: 10.1001/jama.2009.1619

36. Kingwell BA, Chapman MJ, Kontush A, Miller NE. HDL-targeted therapies: progress, failures and future. *Nat Rev Drug Discovery* (2014) 13:445–64. doi: 10.1038/nrd4279

37. Perkins RK, Miranda ER, Karstoft K, Beisswenger PJ, Solomon TPJ, Haus JM. Experimental hyperglycemia alters circulating concentrations and renal clearance of oxidative and advanced glycation end products in healthy obese humans. *Nutrients* (2019) 11:532. doi: 10.3390/nu11030532

38. Irving BA, Carter RE, Soop M, Weymiller A, Syed H, Karakelides H, et al. Effect of insulin sensitizer therapy on amino acids and their metabolites. *Metabolism* (2015) 64:720–8. doi: 10.1016/j.metabol.2015.01.008

39. Razquin C, Ruiz-Canela M, Clish CB, Li J, Toledo E, Dennis C, et al. Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies. *Cardiovasc Diabetol* (2019) 18:151. doi: 10.1186/s12933-019-0958-2

40. Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, et al. HIV and antiretroviral therapy-related fat alterations. *Nat Rev Dis Primers* (2020) 6:48. doi: 10.1038/s41572-020-0181-1

41. Dugas LR, Chorell E, Plange-Rhule J, Lambert EV, Cao G, Cooper RS, et al. Obesity-related metabolite profiles of black women spanning the epidemiologic transition. *Metabolomics* (2016) 12:45. doi: 10.1007/s11306-016-0960-6

42. Libert DM, Nowacki AS, Natowicz MR. Metabolomic analysis of obesity, metabolic syndrome, and type 2 diabetes: amino acid and acylcarnitine levels change along a spectrum of metabolic wellness. *PeerJ* (2018) 6:e5410. doi: 10.7717/peerj.5410

43. Xu W-Y, Shen Y, Zhu H, Gao J, Zhang C, Tang L, et al. 2-Aminoadipic acid protects against obesity and diabetes. *J Endocrinol* (2019) 243:111–23. doi: 10.1530/JOE-19-0157

44. Xu W-Y, Zhu H, Shen Y, Wan Y-H, Tu X-D, Wu W-T, et al. DHTKD1 deficiency causes Charcot-Marie-Tooth disease in mice. *Mol Cell Biol* (2018) 38:13. doi: 10.1128/MCB.00085-18

45. Gao X, Zhang W, Wang Y, Pedram P, Cahill F, Zhai G, et al. Serum metabolic biomarkers distinguish metabolically healthy peripherally obese from unhealthy centrally obese individuals. *Nutr Metab (Lond)* (2016) 13:33. doi: 10.1186/s12986-016-0095-9

46. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. *Circulation* (2008) 118:e29–35. doi: 10.1161/CIRCULATIONAHA.107.189624

47. Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. *Aliment Pharmacol Ther* (2015) 41:368–78. doi: 10.1111/apt.13052

48. Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. *AIDS* (2017) 31:1621–32. doi: 10.1097/QAD.0000000000001504

49. Nansseu JR, Bigna JJ, Kaze AD, Noubiap JJ. Incidence and risk factors for prediabetes and diabetes mellitus among HIV-infected adults on antiretroviral therapy: A systematic review and meta-analysis. *Epidemiology* (2018) 29:431–41. doi: 10.1097/EDE.0000000000000815